{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T16:24:13Z","timestamp":1785774253725,"version":"3.56.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Qual Life Res"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s11136-015-1187-0","type":"journal-article","created":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T02:21:45Z","timestamp":1448936505000},"page":"1505-1515","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Health-related quality of life in Parkinson\u2019s: impact of \u2018off\u2019 time and stated treatment preferences"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3921-0841","authenticated-orcid":false,"given":"Cicely","family":"Kerr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily J.","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte E.","family":"Kosmas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen T.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karissa","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"McIntosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,1]]},"reference":[{"key":"1187_CR1","first-page":"S40","volume":"14","author":"D Weintraub","year":"2010","unstructured":"Weintraub, D., Comella, C. L., & Stacy, H. (2010). Parkinson\u2019s disease\u2014Part 1: Pathophysiology, symptoms, burden, diagnosis, and assessment. The American Journal of Managed Care, 14, S40\u2013S48.","journal-title":"The American Journal of Managed Care"},{"key":"1187_CR2","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/WNF.0b013e31828f3385","volume":"36","author":"T M\u00fcller","year":"2013","unstructured":"M\u00fcller, T. (2013). Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson\u2019s disease: Focus on levodopa\/carbidopa\/entacapone for treatment of levodopa-associated motor complications. Clinical Neuropharmacology, 36, 84\u201391.","journal-title":"Clinical Neuropharmacology"},{"issue":"12","key":"1187_CR3","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1002\/mds.23875","volume":"26","author":"A Antonini","year":"2011","unstructured":"Antonini, A., Martinez-Martin, P., Chaudhuri, R. K., Merello, M., Hauser, R., Katzenschlager, R., et al. (2011). Wearing-off scales in Parkinson\u2019s disease: Critique and recommendations. Movement Disorders, 26(12), 2169\u20132175.","journal-title":"Movement Disorders"},{"key":"1187_CR4","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1517\/14656566.7.10.1399","volume":"7","author":"F Stocchi","year":"2006","unstructured":"Stocchi, F. (2006). The levodopa wearing-off phenomenon in Parkinson\u2019s disease: Pharmacokinetic considerations. Expert Opinion on Pharmacotherapy, 7, 1399\u20131407.","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"1187_CR5","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1586\/ern.11.195","volume":"12","author":"RA Hauser","year":"2012","unstructured":"Hauser, R. A. (2012). IPX066: A novel carbidopa-levodopa extended-release formulation. Expert Review of Neurotherapeutics, 12, 133\u2013140.","journal-title":"Expert Review of Neurotherapeutics"},{"key":"1187_CR6","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/pr.111.005678","volume":"65","author":"P Huot","year":"2013","unstructured":"Huot, P., Johnston, T. H., Koprich, J. B., Fox, S. H., & Brotchie, J. M. (2013). The pharmacology of L-DOPA-induced dyskinesia in Parkinson\u2019s disease. Pharmacological Reviews, 65, 171\u2013222.","journal-title":"Pharmacological Reviews"},{"key":"1187_CR7","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000098468","volume":"57","author":"JC Gomez-Esteban","year":"2007","unstructured":"Gomez-Esteban, J. C., Zarranz, J. J., Lezcano, E., Tijero, B., Luna, A., Velasco, F., et al. (2007). Influence of motor symptoms upon the quality of life of patients with Parkinson\u2019s disease. European Neurology, 57, 161\u2013165.","journal-title":"European Neurology"},{"issue":"2","key":"1187_CR8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/0891988708328219","volume":"22","author":"S Montel","year":"2009","unstructured":"Montel, S., Bonnet, A. M., & Bungener, C. (2009). Quality of life in relation to mood, coping strategies, and dyskinesia in Parkinson\u2019s disease. Journal of Geriatric Psychiatry, 22(2), 95\u2013102.","journal-title":"Journal of Geriatric Psychiatry"},{"issue":"10","key":"1187_CR9","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/mds.21667","volume":"23","author":"S Rahman","year":"2008","unstructured":"Rahman, S., Griffin, H. J., Quinn, N. P., & Jahanshahi, M. (2008). Quality of life in Parkinson\u2019s disease: The relative importance of the symptoms. Movement Disorders, 23(10), 1428\u20131434.","journal-title":"Movement Disorders"},{"issue":"7","key":"1187_CR10","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1023\/A:1008903126315","volume":"9","author":"CS Palmer","year":"2000","unstructured":"Palmer, C. S., Schmier, J. K., Snyder, E., & Scott, B. (2000). Patient preferences and utilities for \u2018off-time\u2019 outcomes in the treatment of Parkinson\u2019s disease. Quality of Life Research, 9(7), 819\u2013827.","journal-title":"Quality of Life Research"},{"key":"1187_CR11","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman, M., Gudex, C., Lloyd, A., Janssen, M., Kind, P., Parkin, D., et al. (2011). Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality of Life Research, 20, 1727\u20131736.","journal-title":"Quality of Life Research"},{"key":"1187_CR12","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/ageing\/26.5.353","volume":"26","author":"C Jenkinson","year":"1997","unstructured":"Jenkinson, C., Fitzpatrick, R., Peto, V., Greenhall, R., & Hyman, N. (1997). The Parkinson\u2019s Disease Questionnaire (PDQ-39): Development and validation of Parkinson\u2019s disease summary index score. Age and Ageing, 26, 353\u2013357.","journal-title":"Age and Ageing"},{"key":"1187_CR13","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun, V., & Clarke, V. (2006). Using thematic analysis in psychology. Qualitative Research in Psychology, 3, 77\u2013101.","journal-title":"Qualitative Research in Psychology"},{"key":"1187_CR14","first-page":"153-163","volume-title":"Recent developments in Parkinson\u2019s disease, Vol 2","author":"S Fahn","year":"1987","unstructured":"Fahn, S., & Elton, R. L. (1987). Members of the UPDRS Development Committee. The United Parkinson\u2019s Disease Rating Scale. In S. Fahn, C. D. Marsden, D. B. Caine, & M. Goldstein (Eds.), Recent developments in Parkinson\u2019s disease, Vol 2 (pp. 153-163\u2013293-304). Florham Park: Macmillian Healthcare Information."},{"issue":"9","key":"1187_CR15","doi-asserted-by":"crossref","first-page":"855","DOI":"10.2165\/00019053-200624090-00004","volume":"24","author":"E McIntosh","year":"2006","unstructured":"McIntosh, E. (2006). Using stated preference discrete choice experiments in cost-benefit analysis: Some considerations. Pharmacoeconomics, 24(9), 855\u2013869.","journal-title":"Pharmacoeconomics"},{"key":"1187_CR16","volume-title":"Handbooks in health economic evaluation","author":"E McIntosh","year":"2010","unstructured":"McIntosh, E., Clarke, P., Frew, E., & Louviere, J. J. (2010). Applied methods of cost-benefit analysis in health care. In A. Gray & A. Briggs (Eds.), Handbooks in health economic evaluation. Oxford: Oxford University Press."},{"issue":"1","key":"1187_CR17","first-page":"55","volume":"2","author":"M Ryan","year":"2003","unstructured":"Ryan, M., & Gerard, K. (2003). Using discrete choice experiments to value health care programmes: Current practice and future research reflections. Applied health economics and health policy, 2(1), 55\u201364.","journal-title":"Applied health economics and health policy"},{"issue":"4","key":"1187_CR18","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","volume":"14","author":"JF Bridges","year":"2011","unstructured":"Bridges, J. F., Hauber, A. B., Marshall, D., Lloyd, A., Prosser, L. A., Regier, D. A., et al. (2011). Conjoint analysis applications in health\u2014a checklist: A report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value in Health, 14(4), 403\u2013413.","journal-title":"Value in Health"},{"issue":"4","key":"1187_CR19","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1524-4733.2008.00459.x","volume":"12","author":"S Petrou","year":"2009","unstructured":"Petrou, S., & McIntosh, E. (2009). Using discrete choice experiments to elicit women\u2019s preferences for alternative forms of miscarriage management. Value in Health, 12(4), 551\u2013559.","journal-title":"Value in Health"},{"issue":"3","key":"1187_CR20","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2165\/00019053-200725030-00005","volume":"25","author":"DF Ossa","year":"2007","unstructured":"Ossa, D. F., Briggs, A., McIntosh, E., Cowell, W., Littlewood, T., & Sculpher, M. (2007). Using direct utility elicitation and discrete choice studies to assess the impact of chemotherapy-related anaemia on the health-related quality-of-life of cancer, and the value of rHu-EPO treatment. Pharmacoeconomics, 25(3), 223\u2013237.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"1187_CR21","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3132\/pcrj.2007.00052","volume":"16","author":"A Lloyd","year":"2007","unstructured":"Lloyd, A., McIntosh, E., Rabe, K., & Williams, A. (2007). Patient preferences for asthma therapy: A discrete choice experiment. Primary Care Respiratory Journal, 16(4), 241\u2013248.","journal-title":"Primary Care Respiratory Journal"},{"key":"1187_CR22","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1001\/archinte.162.12.1361","volume":"162","author":"L Kleinman","year":"2002","unstructured":"Kleinman, L., McIntosh, E., Ryan, M., Schmier, J., Crawley, J., Locke, G. R., & de Lissovoy, G. (2002). Willingness to pay for complete symptom relief of gastroesophageal reflux disease. Archives of Internal Medicine, 162, 1361\u20131366.","journal-title":"Archives of Internal Medicine"},{"issue":"2","key":"1187_CR23","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/pubmed\/22.2.202","volume":"22","author":"M Ryan","year":"2000","unstructured":"Ryan, M., McIntosh, E., Dean, T., & Old, P. (2000). Trade offs between location and waiting times in the provision of health care: The case of elective surgery on the Isle of Wight. Journal of Public Health Medicine, 22(2), 202\u2013210.","journal-title":"Journal of Public Health Medicine"},{"key":"1187_CR24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/PROM.S29443","volume":"3","author":"N Hattori","year":"2012","unstructured":"Hattori, N., Fujimoto, K., Kondo, T., Murata, M., & Stacy, M. (2012). Patient perspectives on Parkinson\u2019s disease therapy in Japan and the United States: Results of two patient surveys. Patient Related Outcomes Measures, 3, 31\u201338.","journal-title":"Patient Related Outcomes Measures"},{"issue":"1","key":"1187_CR25","first-page":"288","volume":"134","author":"L Burgess","year":"2005","unstructured":"Burgess, L., & Street, D. J. (2005). Optimal designs for choice experiments with asymmetric attributes. Journal of Statistical Physics, 134(1), 288\u2013301.","journal-title":"Journal of Statistical Physics"},{"issue":"5","key":"1187_CR26","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","volume":"15","author":"B Hout van","year":"2012","unstructured":"van Hout, B., Janssen, M. F., Feng, Y. S., Kohlmann, T., Busschbach, J., Golicki, D., et al. (2012). Interim scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L value sets. Value in Health, 15(5), 708\u2013715.","journal-title":"Value in Health"},{"key":"1187_CR27","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/00019053-200826080-00004","volume":"26","author":"E Lancsar","year":"2008","unstructured":"Lancsar, E., & Louviere, J. (2008). Conducting discrete choice experiments to inform healthcare decision making. Pharmacoeconomics, 26, 661\u2013677.","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"1187_CR28","doi-asserted-by":"crossref","first-page":"616","DOI":"10.18553\/jmcp.2010.16.8.616","volume":"16","author":"FR Johnson","year":"2010","unstructured":"Johnson, F. R., Hauber, B., Ozdemir, S., Siegel, C. A., Hass, S., & Sands, B. E. (2010). Are gastroenterologists less tolerant of treatment risks than patients? Benefit-risk preferences in Crohn\u2019s disease management. Journal of Managed Care Pharmacy, 16(8), 616\u2013628.","journal-title":"Journal of Managed Care Pharmacy"},{"issue":"6","key":"1187_CR29","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s11136-004-7713-0","volume":"14","author":"SJ Walters","year":"2005","unstructured":"Walters, S. J., & Brazier, J. E. (2005). Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Quality of Life Research, 14(6), 1523\u20131532.","journal-title":"Quality of Life Research"},{"key":"1187_CR30","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1477-7525-5-70","volume":"5","author":"AS Pickard","year":"2007","unstructured":"Pickard, A. S., Neary, M. P., & Cella, D. (2007). Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes, 5, 70.","journal-title":"Health Qual Life Outcomes"},{"issue":"2","key":"1187_CR31","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/mds.20279","volume":"20","author":"S Chapuis","year":"2005","unstructured":"Chapuis, S., Ouchchane, L., Metz, O., Gerbaud, L., & Durif, F. (2005). Impact of the motor complications of Parkinson\u2019s disease on the quality of life. Movement Disorders, 20(2), 224\u2013230.","journal-title":"Movement Disorders"},{"issue":"2","key":"1187_CR32","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1365-2648.2010.05459.x","volume":"67","author":"A Haahr","year":"2011","unstructured":"Haahr, A., Kirkevold, M., Hall, E. O., & \u00d8stergaard, K. (2011). Living with advanced Parkinson\u2019s disease: A constant struggle with unpredictability. Journal of Advanced Nursing, 67(2), 408\u2013417.","journal-title":"Journal of Advanced Nursing"},{"issue":"1","key":"1187_CR33","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/mds.10642","volume":"19","author":"C Marras","year":"2004","unstructured":"Marras, C., Lang, A., Krahn, M., Tomlinson, G., & Naglie, G. (2004). Quality of life in early Parkinson\u2019s disease: Impact of dyskinesias and motor fluctuations. Movement Disorders, 19(1), 22\u201328.","journal-title":"Movement Disorders"},{"issue":"3","key":"1187_CR34","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s00415-010-5786-y","volume":"258","author":"JC G\u00f3mez-Esteban","year":"2011","unstructured":"G\u00f3mez-Esteban, J. C., Tijero, B., Somme, J., Ciordia, R., Berganzo, K., Rouco, I., et al. (2011). Impact of psychiatric symptoms and sleep disorders on the quality of life of patients with Parkinson\u2019s disease. Journal of Neurology, 258(3), 494\u2013499.","journal-title":"Journal of Neurology"},{"issue":"10","key":"1187_CR35","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/mds.22121","volume":"23","author":"EB Forsaa","year":"2008","unstructured":"Forsaa, E. B., Larsen, J. P., Wentzel-Larsen, T., Herlofson, K., & Alves, G. (2008). Predictors and course of health-related quality of life in Parkinson\u2019s disease. Movement Disorders, 23(10), 1420\u20131427.","journal-title":"Movement Disorders"},{"issue":"15","key":"1187_CR36","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz, C. G., Tilley, B. C., Shaftman, S. R., Stebbins, G. T., Fahn, S., Martinez-Martin, P., et al. (2008). Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Movement Disorders, 23(15), 2129\u20132170.","journal-title":"Movement Disorders"},{"key":"1187_CR37","doi-asserted-by":"crossref","first-page":"e651","DOI":"10.1016\/j.jns.2013.07.2259","volume":"333","author":"D Morley","year":"2013","unstructured":"Morley, D., Dummett, S., Kelly, L., Dawson, J., Fitzpatrick, R., & Jenkinson, C. (2013). Development of the Oxford Participation & Activities Questionnaire: Semi structured interviews with potential users. Journal of the Neurological Sciences, 333, e651.","journal-title":"Journal of the Neurological Sciences"}],"container-title":["Quality of Life Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-015-1187-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11136-015-1187-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-015-1187-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T03:59:48Z","timestamp":1559361588000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11136-015-1187-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,1]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["1187"],"URL":"https:\/\/doi.org\/10.1007\/s11136-015-1187-0","relation":{},"ISSN":["0962-9343","1573-2649"],"issn-type":[{"value":"0962-9343","type":"print"},{"value":"1573-2649","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,1]]}}}